Lupin receives US FDA approval to market generic Ancobon capsules
DSIJ Intelligence / 10 Jul 2017
Lupin’s Flucytosine Capsules USP, 250 mg and 500 mg are AB rated generic equivalent of Valeant Pharmaceuticals International Inc’s Ancobon Capsules, 250 mg and 500 mg. Ancobon capsules had US sales of USD 46.6 million.
On Monday,Lupin Limited has received final approval for its Flucytosine Capsules USP, 250 mg and 500 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Valeant Pharmaceuticals International Inc’s Ancobon Capsules, 250 mg and 500 mg.
Lupin’s Flucytosine Capsules USP, 250 mg and 500 mg are AB rated generic equivalent of Valeant Pharmaceuticals International Inc’s Ancobon Capsules, 250 mg and 500 mg. Ancobon capsules had US sales of USD 46.6 million.
Flucytosine Capsules USP, 250 mg and 500 mg are indicated for the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus.